NEW YORK , Aug. 28, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX ), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that the company will host a Multiple Sclerosis (MS) Research and Development (R&D) Day and participate in the following scientific and investor conferences in September: September 10 : Immunic's MS R&D Day.
Management of Immunic, including Daniel Vitt , Ph.D., Chief Executive Officer; Jason Tardio , M.
B.A., Chief Operating Officer and President; Andreas Muehler , M.
D., M.B.
A., Chief Medical Officer; and Hella Kohlhof , Ph.D.
, Chief Scientific Officer, will be joined by two of the MS industry's renowned experts to discuss the MS landscape as well as Immunic's orally available lead-asset, nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium (IMU-838) and its potential to become the treatment of choice for both relapsing and progressive MS patients. Date: Tuesday, September 10, 2024 Time: 10:30 am to 12:30 pm ET , followed by a networking lunch Location: One Five One, 151 West 42nd Street, New York, NY 10036 Featured Experts: Francesca Montarolo, Ph.D.
, Neuroscience Institute Cavalieri Ottolenghi (NICO) and University Hospital San Luigi Gonzaga of Orbassano, Turin, Italy Amit Bar-Or, M.D., FRCPC, Melissa and Paul Anderson Distinguished Chair, Director, Center for Neuroinflammation and Experimental Therapeutics, Chief, Multiple.